MX2023001740A - Metodos de tratamiento de la gota. - Google Patents

Metodos de tratamiento de la gota.

Info

Publication number
MX2023001740A
MX2023001740A MX2023001740A MX2023001740A MX2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A
Authority
MX
Mexico
Prior art keywords
methods
treating gout
pegylated uricase
mtx
administering
Prior art date
Application number
MX2023001740A
Other languages
English (en)
Inventor
Paul Peloso
Brian Lamoreaux
Swarnendra Verma
Original Assignee
Horizon Therapeutics Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Usa Inc filed Critical Horizon Therapeutics Usa Inc
Publication of MX2023001740A publication Critical patent/MX2023001740A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción proporciona métodos de tratamiento de la gota en pacientes que comprenden administrar una uricasa PEGilada en un período de infusión acortado inferior a 120 minutos y un volumen de infusión acortado de menos de 250 ml. También se proporcionan métodos de tratamiento de la gota en pacientes que comprenden coadministrar una uricasa PEGilada y metotrexato (MTX). También se proporcionan métodos de reducción de la inmunogenicidad de una uricasa PEGilada y prolongación del efecto hipouricemiante que comprenden la coadministración de la uricasa PEGilada y MTX.
MX2023001740A 2020-08-10 2021-08-10 Metodos de tratamiento de la gota. MX2023001740A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063826P 2020-08-10 2020-08-10
US202163148982P 2021-02-12 2021-02-12
PCT/US2021/045350 WO2022035828A1 (en) 2020-08-10 2021-08-10 Methods of treating gout

Publications (1)

Publication Number Publication Date
MX2023001740A true MX2023001740A (es) 2023-04-05

Family

ID=80247297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001740A MX2023001740A (es) 2020-08-10 2021-08-10 Metodos de tratamiento de la gota.

Country Status (11)

Country Link
US (2) US20230301999A1 (es)
EP (1) EP4192581A1 (es)
JP (1) JP2023537403A (es)
KR (1) KR20230086660A (es)
CN (1) CN116261463A (es)
AU (1) AU2021324665A1 (es)
BR (1) BR112023002458A2 (es)
CA (1) CA3189100A1 (es)
IL (1) IL300536A (es)
MX (1) MX2023001740A (es)
WO (1) WO2022035828A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604399A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
EP3482768A1 (en) 2009-06-25 2019-05-15 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2024088213A1 (en) * 2022-10-24 2024-05-02 Westlake Therapeutics (Shanghai) Co., Limited Combination to induce specific immune tolerance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200237881A1 (en) * 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase

Also Published As

Publication number Publication date
CA3189100A1 (en) 2022-02-17
BR112023002458A2 (pt) 2023-05-02
AU2021324665A1 (en) 2023-04-13
US20220323445A1 (en) 2022-10-13
WO2022035828A1 (en) 2022-02-17
IL300536A (en) 2023-04-01
KR20230086660A (ko) 2023-06-15
EP4192581A1 (en) 2023-06-14
CN116261463A (zh) 2023-06-13
US20230301999A1 (en) 2023-09-28
JP2023537403A (ja) 2023-08-31

Similar Documents

Publication Publication Date Title
MX2023001740A (es) Metodos de tratamiento de la gota.
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2002043720A3 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2003037313A3 (en) Methods for the treatment of addiction
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
HUP0303927A2 (hu) Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre
HUP0102489A2 (hu) Biokémiai anyagok alkalmazása emberi test szerveiben található simaizomsejtek összehúzódása okozta egészségi állapotok megelőzésére és kezelésére alkalmas készítményekben
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
WO2004046196A3 (en) Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
MY125984A (en) Pharmaceutical solutions of levosimendan.
IL165858A (en) Pharmaceutical preparation for treating human malignancies with arginine deprivation and uses thereof
EP1383516A4 (en) CO-ADMINISTRATION OF A POLYSACCHARIDE WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CANCER
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
AP1896A (en) The method of treating cancer
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
MX2023006294A (es) Proteinas de union a il-7 y su uso en tratamientos medicos.
MX2023001140A (es) Uso del dexpramipexol para el tratamiento de asma moderado a grave.
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
WO2004045497A3 (en) Cd26-based therapies for cancers and immune disease
UA85548C2 (ru) Применение водного экстракта листьев красного винограда для предупреждения перехода от клинически незначительных ранних стадий хронической венозной недостаточности к i, ii или iii стадии
Myerson et al. Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma
Jang et al. Radiologically-Placed Venous Ports in Children Under Venous Anesthesia.
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
AU2003229876A1 (en) Tumour associated antigens